The Federal Pain Research Strategy is an effort of the Interagency Pain Research Coordinating Committee and the Office of Pain Policy of the National Institutes of Health to oversee development of a long-term strategic plan for those federal agencies and departments that support pain research. A diverse and balanced group of scientific experts, patient advocates, and federal representatives identified and prioritized research recommendations as a basis for this long-term strategic plan to coordinate and advance the federal pain research agenda. The key areas of prevention of acute and chronic pain, acute pain and acute pain management, the transition from acute to chronic pain, chronic pain and chronic pain management, and disparities in pain and pain care provided the framework for development of the strategy. In addition, a set of cross-cutting research priorities were identified by the task force in topic areas for which similar research recommendations were developed across multiples work groups and merged.

CROSS-CUTTING PRIORITIES

NOVEL DRUGS AND NON-PHARMACOLOGICAL TREATMENTS FOR PAIN

Statement of the Problem
Current mainstays of pain management, including analgesics and anesthetics, are used despite known side effects. Of note, no new pharmacologic treatment for pain has emerged in clinical practice for some time. Instead, modifications and combinations of established therapeutic molecules were developed and evaluated with little improvements in efficacy or reduction of adverse effects. Given the adverse effects, risks of tolerance, dependence, and addiction, associated with opioids, new safer and more effective pharmacologic and non-pharmacologic approaches for pain management are needed. Data and knowledge gaps have prevented promising in basic research findings from being translated into safe and effective therapies.

Research Priorities

Development of safe and effective pharmacologic approaches for pain is an important goal that will greatly benefit patients and healthcare providers. To achieve this goal, drug discovery efforts that target
endogenous resolution mechanisms and/or mechanisms that can move patients toward new, acceptable set-points should be prioritized. Government support of early stage drug development in this area should be enhanced.

**Evaluate Efficacy, Safety and Interactions of New Therapies.**
As part of any evaluation of a new therapy for pain management, data needs to be collected on efficacy, adverse effects, interactive effects with other treatments, and interactions with and impact on patient’s comorbid conditions. Determination of optimal dosing and adherence strategies for non-pharmacological treatments should be part of the evaluation process. Differential effects of novel therapies on disparate groups (e.g. young, elderly, should be explored). Of note, it may be inappropriate to expect that therapeutics, which are effective in men also are effective in women. Further research on neuraxial and peripheral regional analgesia is needed, including methods of delivery, for example – optimization of catheter insertion and ambulatory infusion techniques, infusate(s) and adjuvants, and prevention of rare adverse effects.

**Explore Novel Biological Targets.**
Discovery and evaluation of biologics as new pharmacologic and non-pharmacologic treatments for pain that are safe and effective is needed. Research on these targets should be based on knowledge of the biopsychosocial mechanisms underlying pain.

**SCREENING TOOLS AND OUTCOME MEASURES FOR ASSESSMENTS ACROSS THE CONTINUUM OF PAIN**

**Statement of the Problem**
Pain is a subjective experience and difficult to measure objectively. Biomarkers could provide means to objectify an inherently subjective measurement. In addition to identifying pain states and helping clinicians classify pain, biomarkers could guide treatment and prognosis, and help predict effectiveness and risks of treatment. Functional imaging and measures of inflammatory markers (e.g. cytokines, nerve growth factors) have potential to identify unique pain “signatures”, but have not yet proven to provide appropriate clinical measures. It is generally acknowledged that pain cannot be measured in isolation, but rather in conjunction with other outcome measures in non-pain domains. Pain is associated with non-pain “domains” that may be affected by- and affect- pain including sleep, mood, cognition, function, and quality of life. For example, although minimal clinically important differences have been established for pain and for most other non-pain outcome measures (e.g. sleep, function, mood), improvement in pain without concomitant improvement in other domains may not constitute a clinically meaningful improvement. Combined outcome measures are being used more often in clinical trials as their utility is recognized. Objectively measuring pain and predicting which patients are at risk for developing persistent or recurrent pain and responsiveness to treatment are of utmost importance.
Research Priorities

Standardize Outcome Measures and Define Treatment Effects
Research to develop, evaluate, and disseminate standardized outcome measures for different clinical conditions, determine what constitutes a clinically meaningful effect, and determine which outcome domains to measure is crucial to successful implementation and interpretation of clinical trials of pain treatments. This research should address what constitutes a clinically meaningful outcome in the various relevant core domains and whether these outcomes differ across disparate populations.

Discovery and Evaluate Biomarker Information
Biomarkers for acute pain management – Research is needed that leverages quality patient-reported outcomes data across a variety of domains and correlates these data with biomarker information. This research needs to be done across a variety of common pain conditions.

Develop Screeners for Predictor Variables of Persistent and/or Recurrent Pain
Research is needed to develop and optimize the accuracy of screening tools that are predictive of development of persistent or recurrent and/or resilience to pain. Such tools need to be developed across the translational spectrum including biological, psychological, and social approaches.

NATIONAL REGISTRIES, DATASETS & RESEARCH NETWORKS

Statement of the Problem
The paucity of large data sets and prospective registries of well-characterized patients has delayed our understanding of chronic pain and development of safe and effective pain management. Such resources will allow researchers to follow prospectively, sizable patient populations, pool large data sets through standardized data-sharing repositories, and utilize “big data” approaches, including comparative and cost effectiveness analyses. Information generated from these resources will help to elucidate the complex heterogeneity of chronic pain, identify populations vulnerable to developing chronic pain, and discriminate subgroups who benefit from different pharmacological and non-pharmacologic treatments and treatment algorithms. Furthermore, given the heterogeneity within and across chronic pain disorders and populations, large data sets will increase the likelihood of delineating the complex interplay among genetic, environmental, physiological, psychological and clinical characteristics that contribute to the risk of developing, clinical course, and treatment of chronic pain.

Research Priorities

Develop a Research Network.
Development of a research network that would study diverse chronic pain conditions using standard phenotyping and mechanistic techniques is needed. This will require a core for data coordinating and other functions and discovery sites for specific pain conditions, which will add to the scientific power of the network. Discovery sites should cover a wide variety of pain conditions (from nociceptive/neuropathic to centralized), and longitudinally follow individuals who receive standard patient reported outcome
batteries and mechanistic studies, and are exposed to active (pharmacological and non-pharmacological) treatments. This may be accomplished by incorporating the registry/database into primary healthcare settings and cross-linking with broader healthcare registries. These longitudinal studies should include participants from disparate populations, span the lifespan, and include all socioeconomic strata. Registries and databases should target the general patient population rather than be limited to those seen in specialty pain clinics. A crucial component of these networks should be to integrate preclinical researchers that can reverse translate findings into animal and other models to further elucidate mechanisms.

Determine Similarities and Difference Across Chronic Pain States.
Utilize these data resources to determine the similarities and difference across chronic pain states, as well as the crucial phenotypic and biomarker features that predict responsiveness to treatments. This structure also will help optimize the value of preclinical pain research, by enabling clinical studies to drive the most important scientific questions that can be answered only by reverse translation. By studying clinical pain conditions side by side, and probing potential mechanisms from the periphery to the CNS while individuals are receiving treatments, we will be able to translate research into the clinic.

Standardize Data Collection and Evaluation.
Develop and utilize minimum data sets and common data elements (including those within electronic health records) that provide a comprehensive assessment of the chronic pain experience.

Leverage and Expand Current Data Resources.
Expand large healthcare databases to facilitate studies of chronic pain risk factors and potential resilience factors across the lifespan with unprecedented patient numbers.

EFFECTIVE MODELS OF CARE DELIVERY FOR PAIN MANAGEMENT

Statement of the Problem
Despite the significant burden of pain, effective programs, services, and interventions are not always accessible, available, or utilized. In particular, disparate groups such as socioeconomically disadvantaged individuals may not have access to many care services, interventions or preventative health care programs. A void exists in understanding models of care outside the hospital such as in emergency (e.g., ambulance) and home care settings. Health system and financial arrangements do not consistently support effective, low cost, low risk interventions over those interventions that are higher cost and higher risk. While clinical research has established some effective and cost-effective chronic pain interventions, there are a significant number of interventions that have not been evaluated adequately.

Research Priorities

Develop, Evaluate, Improve Models of Pain Care.
Research is needed to develop new or improve current models of primary, secondary, tertiary care to improve pain management along the continuum of the pain experience. Research should address all levels of care, in varied care settings, and across the lifespan, including palliative care. Research should include studies on models of integrated care, team care delivery, and reimbursement innovations. Such studies should incorporate and evaluate new and existing technologies identify the best approaches to balance
safety, effectiveness, and costs of care for individuals with pain to inform models of service delivery and reimbursement and to improve access to quality pain management.

**Determine the Benefits, Risks, and Costs of Pain Treatments.**
Utilize knowledge translation, clinical trials, and cost-effectiveness studies to determine the benefits, risks, and costs of various pain treatments alone and in combinations including patient-centered primary care chronic pain management, the roles of specialty and tertiary care, optimal strategies for tailoring pain therapies to individuals, and strategies to reduce disparities in chronic pain management.

**Assess Effects of Policy Changes on Pain Care.**
Research to determine how regulatory policies impact access to care and which methods best incentivize innovation in models of care are needed. Research should address organizational, provider, and patient barriers to engagement in effective treatments including understanding of stigma related to chronic pain. Particular attention should be paid to understanding barriers and stigmas in disparate populations. Rigorous evaluation is needed on the impact of reimbursement innovations on pain care quality measures and cost savings. Effective methods to disseminate research findings and incentives to incorporate them into clinical practice need to be studied.

**PRECISION MEDICINE METHODOLOGY TO PREVENT AND TREAT PAIN**

**Statement of the Problem**
Precision medicine is an approach to disease prevention and treatment that takes into account biological, psychological, environmental and other patient-specific factors. This approach directly addresses the wide inter-individual differences typically observed in pain severity, treatment responsiveness, and side effect frequency. The significance of this approach for pain care will be profound as we move from generalized to personalized treatment approaches.

**Research Priorities**

**Develop Approaches Incorporating the Principles of Precision Medicine to Prevent and Effectively Treat Chronic Pain.**
The discovery and validation of markers, measures, and combinations of these factors predictive of an individual’s susceptibility to chronic pain of specific types is needed. Identification of patient-specific factors associated with favorable versus poor responsiveness to specific treatments. Establish genetic and environmental factors predictive of adverse treatment outcomes such as medication-related side effects, organ toxicity and addiction. Develop biostatistical methodologies to combine and weight patient specific factors for the purposes of enhancing diagnostic accuracy and optimizing treatment selection.
Statement of the problem
The morbidity and costs of pain-related conditions often are driven by injuries or acute conditions that are refractory to care and eventually become chronic. Comorbid medical conditions, psychosocial disorders, personal behaviors, and lifestyle factors may contribute to the onset, persistence, and related disability of chronic pain. Primary prevention of pain is defined as preventing acute pain and may be approached best through a public health model of care aimed at both the general population and high-risk groups. Secondary prevention is defined as prevention of the transition from acute to chronic pain. Tertiary prevention is aimed at reducing the frequency, severity and disability of chronic pain. Although a relatively small proportion of patients with acute pain go on to experience persistent pain, they account for most of the expenditures and disability associated with pain conditions.

Research Priorities

Optimize Public Health Strategies to Educate Patients on Managing Pain.
Public understanding of pain should address the complex biological and psychosocial aspects of pain. Evidence-based materials should be developed on the nature of pain and ways to use self-management strategies to prevent, cope with, and reduce pain. Research is needed on the methods and materials that will be most effective in targeting the public at large, patients, and health-care providers. Research topics should include determining which public health strategies, interventions, and modes of delivery, for awareness and education are effective, and what population level interventions are useful for primary, secondary, and tertiary pain prevention and management (e.g., lifestyle changes and environmental changes such as workplace modifications to prevent acute injuries or chronic pain).

Epidemiology of Acute Pain from Health Care Procedures
Data are needed to inform health care providers in guiding patient expectations on the frequency of painful procedures that may occur throughout their lives and the severity and duration of associated pain. This data would guide development of patient-education resources that aim to alleviate fear or anxiety from of pain from common procedures. Research should be focused on establishing the relative onset, severity, duration, and impact of acute pain from common medical (e.g. spinal tap) and surgical (e.g. thoracotomy) procedures. Additional research should examine the incidence of chronic pain that may develop secondary to the acute pain from such procedures (e.g. chronic post-thoracotomy pain) and the impact of such chronic post-procedure pain on other aspects of health and healthcare. Research is particularly encouraged on this topic in vulnerable populations (e.g. premature infants subjected to numerous health care procedures over a short period of time, cancer patients who undergo chemotherapy, radiation, and surgery) and patients with chronic pain.

Evaluate Safety and Effectiveness of Management of Acute Procedure Associated Pain.
Health care procedures are common, frequently cause acute pain and effect a large proportion of the population of all ages. They occur however, in controlled settings where it is feasible to implement interventions aimed at primary prevention of the pain they cause. Research is needed on prevention and mitigation of effects of acute pain. Research is needed on safety and effectiveness of acute pain management for procedures, including the safety and effectiveness of opioid-sparing and multimodal pain...
management protocols currently used to manage acute post-surgical pain. Research is encouraged to identify the optimal multimodal pain prevention protocols based on the type of health care procedure, health care resources available, patient risk/prognostic factors, and patient preferences.

Evaluate Safety and Effectiveness of Early Interventions for Tertiary Prevention.
Research is needed to identify effective tertiary prevention interventions that improve the quality-of-life of persons with chronic pain, as well as reduce costs of care. An important goal of tertiary prevention is to improve function and reduce disability associated with chronic pain, and not merely improve pain-intensity scores. For episodic pain disorders, where there are painful and pain-free intervals, reduction of the frequency of painful episodes also is essential.

Determine Association between Patient and Intervention Factors and Psychosocial Interventions.
Matching of patients to interventions, based on relevant predictive characteristics, would be an effective way to prescribe treatments. Research is needed to explore variation in individual responses to interventions to identify appropriate matching variables. Use randomized controlled trials or observational studies and real-world data (e.g. from pain registries) to determine patient factors (e.g. etiological-physical and emotional trauma, disease/illness, pharmacogenetics); intervention factors (e.g. surgical details, post-surgical approaches, medications); and psychosocial interventions (e.g. education, relaxation, coping skills) that are associated with better outcomes for pain management assessed by responder analysis with matching treatments to subgroups based on subgroup characteristics.

Optimize Post-surgical Approaches for Acute Pain
Surgery is a risk-factor for the development of chronic pain. Given the large number of surgeries that are performed, there is potential for many individuals to develop chronic pain. Research is needed to optimize approaches for acute post-surgical pain management to prevent persistent or recurrent pain and related disability. Genetics, past medical history, musculoskeletal factors, and psychological perspectives are all recognized as potential factors impacting the development of chronic post-surgical pain and as such are areas of interest for the development of optimal secondary prevention strategies.

ACUTE PAIN

Statement of the Problem
Acute pain often is marginalized because many assume that the problem is inherent to illness, trauma, medical procedures, and surgery; necessary to diagnose disease or injury; important for recovery from illness and trauma, including surgery; or solved. However, acute pain assessment and management is commonly inadequate; pharmacologic treatments are imprecise and associated with adverse effects, including substance misuse and abuse; little evidence exists to support the use, dosing, duration, or mechanism of action of biobehavioral treatments; acute pain can be persistent and resistant to treatment; and persistent acute pain can increase the risk for development of chronic pain. Therefore, alternatives measures and treatments are needed to effectively relieve or manage acute pain. There are many types and causes of pain. This heterogeneity is prominent in every aspect of acute pain from transduction of nociceptive signals to psychosocial circumstances that impact interpretation of the pain experience. Molecular and circuit-level understanding of the mechanisms that contribute to acute pain is far from complete. Progress in basic
understanding of these processes will lead to better treatments for acute pain. The optimal approaches to measure and manage acute pain in order to provide tailored interventions for each patient are unknown.

Research Priorities

What are the Molecular Mechanisms of Heterogeneity in Acute Pain Sensation?
At the most basic level, thermal, mechanical, and chemical signals can initiate nociceptor activity or alter activation thresholds. Despite considerable progress in identifying sensors of touch and nociception, major gaps remain. Research to find the identity of mechanically activated ion channels responsible for initiating mechanical nociception (from skin, muscle, or internal organs) needs to be done. Molecular players in sensing temperature (noxious cold) also need to be explored. Advancements in genomics technologies, for example single cell RNAseq, would help tackle these questions. Furthermore, studies on rare, inherited disorders could lead to understanding of nociceptor function that either alters sensitivity to acute noxious stimuli or results in spontaneous pain.

What are the Cellular Mechanisms of Heterogeneity in Acute Pain Sensation?
All forms of stimulus energy (thermal, mechanical, and chemical) can initiate nociceptor activity, although the stimulus adequate for activation is not the same for all nociceptors. Decades of research have focused on stimuli adequate to activate cutaneous nociceptors, including molecules that transduce those energies, but comparable information and understanding of bone/joint, dural, muscle, and visceral nociceptors remains to be established. Given that musculoskeletal, visceral, and cephalic pains are common, it is essential to improving pain management that research be done to bridge this gap. Nociceptors innervating cutaneous tissue are heterogeneous. It should be appreciated that nociceptors that innervate deeper tissues are similarly heterogeneous and dissimilar from cutaneous as well as other deep nociceptors with respect to chemical phenotype, expression of ligand- and ion-gated channels, neuroanatomical location in tissue, etc. Anatomic, genetic, molecular, pharmacological, and physiological approaches that address the unique properties of deep nociceptors are needed to lead to improved understanding of pain mechanisms and pain management.

What are the Contributions of the Autonomic Nervous System to Acute Pain Sensation?
Nociceptor somata in DRG/TG have been the major focus of study, whereas the contribution of the autonomic nervous system to acute pain mechanisms remains largely unknown. Incorporated within the gastrointestinal (GI) tract is an intrinsic nervous system, comprised of intrinsic afferents of enteric neurons within the GI wall. Knowledge of interactions between intrinsic afferents and extrinsic spinal and vagal afferents is scant. Furthermore, interactions of afferents of intrinsic and/or extrinsic nervous systems with sympathetic and parasympathetic efferent neurons conveying information from the CNS are considered important to acute pain mechanisms, but largely unstudied. Neurmodulation of these different nervous systems is a promising treatment for acute pain, although mechanisms of neurmodulation are incompletely understood. Recent developments of in vivo imaging, optogenetics, chemogenetics, and novel animal models should provide means to address these questions.
Heterogeneity of the Circuitry Involved in Acute Pain Sensation and Modulation

Beyond the peripheral nervous system, relatively little is known about distributed networks of neurons across diverse regions of the nervous system that contribute to acute pain. While many of the regions that integrate nociception and give rise to pain have been identified, the underlying neural circuits and the computations they perform are almost completely unknown. Understanding the pain experience will require defining the neuronal cell types that are involved, characterizing how they are connected, and modeling the computations that they execute. The acute pain experience is influenced by expectation, fear, psychological factors (e.g., placebo, nocebos), and repeated exposure to the painful episode and prior experience (learning). Neural signals that entering the nervous system encounter a substrate reflecting such past and present experience. The experience of pain therefore, does not necessarily reflect the state of the tissues. Active modulation of pain occurs from multiple supraspinal regions through descending circuits that modulate spinal and medullary dorsal horn. However, the identity (e.g., neurochemical) of the neurons in these circuits has yet to be identified. Identification of these circuits and their molecular targets is essential for the development of new therapy. Bridging these gaps will require collaborative efforts of molecular geneticists, physiologists, behaviorists, and computational scientists using a variety of approaches including in vivo recordings, population imaging, real-time manipulation of neurons in awake behaving animals, advanced microscopic approaches to understand connectivity, and computational studies.

What Are the Most Sensitive and Specific Preclinical Models of Acute Pain that Are Representative of Naturally Occurring Pain Conditions?

Existing preclinical models have provided valuable insights into acute pain mechanisms. However, to develop new insights and novel therapeutic approaches, preclinical models that are more representative of naturally occurring acute pain conditions (e.g., fractures, burns) need to be developed. In addition, preclinical studies of acute pain need to provide an increased understanding of the mechanisms that underlie changes over time in the experience of acute pain. As part of preclinical research, automated methods need to be developed to monitor spontaneous animal behaviors to elucidate the temporal patterns associated with acute pain. These types of approaches are needed to determine how/what spontaneous (ongoing) measures that can be used in animal research reflect the human experience of postoperative pain that lasts for days. In addition, better measures are needed to evaluate the affective dimension of acute pain in animals.

What Are the Optimal Acute Pain Assessment Parameters and Biopsychosocial Predictors of Acute Pain that Can Be Used to Optimize Individualized Acute Pain Management?

Assessment of acute pain currently relies on a unidimensional rating scale (e.g., 0 to 10 numeric rating scale) that focuses on pain intensity. However, this unidimensional measure does not provide an optimal assessment of an individual’s acute pain management experience or the effectiveness of pain management interventions. Research is needed to determine the optimal parameters (e.g., physical, emotional, cognitive, and functional domains) to include in acute pain assessment to optimize acute pain management for an individual patient. Included in this type of research is a determination of the optimal timing, frequency, and duration for assessments by domain and interventions to best inform clinical decisions and patient outcomes. In addition, work is needed to develop pre-intervention assessment tools to predict the trajectory of pain following interventions. Equally important, research is needed on the appropriate assessments for pain in patients with multiple co-morbidities.
What Are the Acute Pain Assessment Parameters and Biopsychosocial Predictors of Acute Pain that Can Be Used to Optimize Individualized Acute Pain Management in Patients Who Cannot Self-Report?
Research is needed to develop, improve and evaluate measures of responsiveness to pain for individuals who cannot provide self-reports of acute pain. Advanced technology and novel approaches are needed to translate findings, across all pain assessment domains, from animal models and patients who can provide self-report to individuals who cannot provide self-reports of their pain experiences.

What Are the Most Effective Strategies to Provide Optimal Individualized Acute Pain Management of Complex Patients?
Patients at the extremes of age present unique challenges. As the population ages, the numbers of patients with multiple comorbid conditions is increasing. At the other extreme, as our ability to care for premature infants improves, the lack of options for treating very young patients is increasingly problematic. In addition, the numbers of patients with a history of chronic pain with or without concurrent substance use disorders are on the rise. The development and evaluation of strategies to optimize acute pain management of complex patients is warranted.

What are the most effective approaches to deliver evidence-based effective acute pain management programs and how can new and existing technologies improve them within/across various health care systems?
Research is needed that provides practical approaches to evaluate the therapeutic efficacy of acute pain management strategies. This research needs to provide cost effective approaches, incorporate real world settings (including primary care practices and pain self-management programs), and include representative samples of patients. To achieve this research objective may require expansion and leveraging of existing, or development of new pain registries to track clinical and patient-reported outcomes. Research also is needed on how to incorporate new and existing technologies into existing pain management programs. The use of the electronic health record, personal health records, wearable devices, sensors, and other technologies is growing at exponential rates.

TRANSITION TO CHRONIC PAIN

Statement of the Problem
Every day many individuals have the same injury, disease, surgery, or treatment. Many of them experience associated pain, and most of them experience a resolution of pain when the disease is cured, the injury heals, or the treatment stops. However, in a significant portion of these individuals, pain does not resolve and becomes chronic. The factors causing this persisting pain state and mechanisms that govern persistent pain are only beginning to be elucidated. This is a key scientific problem because these factors and mechanisms may hold the key to new therapeutic options to either prevent the development of chronic pain or reverse its course once it becomes persistent. Common risk factors may predispose people to chronic pain. From animal studies, we know that neuronal plasticity and interactions of the nervous system with the immune system are key to persistent pain states. Human brain imaging studies show changes in brain anatomy and function as pain becomes chronic. How these findings fit into a
comprehensive picture of the transition to chronic pain, whether there is such a transition, represents a key gap in knowledge for the field.

Research Priorities

Understanding and Addressing Plasticity Mechanisms that Promote Persistent Pain and (Endogenous) Resolution Mechanisms that May Reverse Persistent Pain
New tools and new lines of research are needed to bridge advances in preclinical research to gaps in our understanding of human molecular neuroscience. Examples include advances in next generation sequencing and/or imaging to enable molecular resolution of mechanisms that drive persistent pain in human patients. As human tissue banks continue to expand in capacity, new lines of research that leverage these resources with advancing technologies should be engaged to test preclinically-defined mechanisms that may give immediate insight into human persistent pain. Moreover, research that utilizes human stem cells to potentially treat and/or to discover pain mechanisms should be encouraged. Research to enable the development of new tools (e.g. optogenetics) for use in the clinic should be encouraged. Researchers using animal models of persistent pain should be encouraged to utilize clinically meaningful endpoints (e.g. assaying cerebrospinal fluid) to enhance translation of preclinical work into clinical diagnostics and/or hypothesis testing.

Whole Brain Imaging in Animal Models Compared to Human Models
Preclinical work can add considerable molecular insight that may never be within reach in the human central nervous system (technologies include light sheet microscopy and tissue clearing techniques such as SCALE, CLARITY and uDISCO). Researchers should develop and/or utilize new technologies to assess brain-wide connectivity changes in animal models that can parallel human imaging work.

Understand How Early and Life Experiences Contribute to Persistent Pain Later in Life.
Despite recent advances, it is still unclear how early life experiences influence long-lasting pain. For instance, are acute pain mechanisms different at birth and/or during adolescence as compared with later in life? In line with this, recent research suggests there are critical periods when organisms may be relatively protected from development of persistent pain from early-life injuries (e.g., brachial plexus avulsion pain in children) or illnesses (e.g., post herpetic neuralgia in younger adults), conditions that produce chronic pain in older adults with high probability. Mechanisms of developmentally-specific pain protective or pain facilitatory periods need to be explored. Research is needed to discover the mechanisms for these developmentally-specific pain protective (or conversely, pain facilitatory), as it has great potential to inform novel therapeutic strategies for chronic pain.

Prospective Studies for Susceptibility and Resilience Factors Underlying the Transition from Acute to Chronic Pain
A general clinical assumption is that there is a linear transition from acute, to subacute, to chronic pain, despite sparse evidence of the basic epidemiology and natural history of the transition. Research is needed to evaluate the course of pain from an acute episode to chronic pain, disability, and flare ups, to understand the complex transition mechanisms and to prevent chronic pain. Trajectories from an acute episode to chronic pain may vary in duration, severity and level of disability. Such information is vital to tailored interventions at critical windows of opportunity. Research should be conducted prospectively to
determine causes for susceptibility to the transition to chronic pain. A goal should be identifying protective factors, including psychosocial factors that can be integrated with other known risk factors. A longitudinal research study is needed on one of the most prevalent and costly pain conditions (e.g., low back pain, headache) to evaluate the different trajectories that occur.

**Mechanistic Trials of Risk & Resilience to Chronic Pain with Meaningful Outcome Measures**
Mechanistic clinical trials should be conducted that target risk and/or resilience and push beyond mere correlation. For example, does therapeutic intervention to decrease catastrophizing prior to surgery reduce chronic pain in this high-risk population? These trials should assess outcomes that are meaningful to patients in addition to simply measuring pain.

**Trials to Determine Acute Pain Management Strategies that Promote or Prevent Development of Chronic Pain**
Preclinical work suggests that certain acute pain management strategies may either promote or prevent the development of persistent pain. It is possible that some strategies for acute pain treatment may impair endogenous resolution mechanisms. This question should be investigated prospectively in targeted clinical trials.

---

**CHRONIC PAIN**

**Statement of the Problem**
The prevalence of chronic pain and the paucity of evidence to determine the best treatments, as well as the rapid rise in opioid misuse and overdose constitute major public health crises. Significant advances have been made in understanding the basic mechanisms of nociception and pain that have led to new potential targets for pain assessment and treatment strategies. Furthermore, recent advances in the neurosciences, biomarkers, and the behavioral sciences have validated a comprehensive approach to the management of pain that includes the individual’s inherent biology, behavior, and psychological makeup and reactions, and their environmental influences. However, data and knowledge gaps remain that have prevented research translation into safe and effective therapies. This is particularly true for chronic pain that occurs in the context of comorbid medical conditions, overlapping comorbid symptoms, and in certain populations including children. In addition, there is increasing recognition that while numerous self-management strategies exist, crucial questions remain regarding their efficacy and effectiveness alone or in combination with other therapeutics. Despite these important research advances on chronic pain, there remain major gaps in our understanding of mechanisms and effective treatments for most chronic pain conditions.
Chronic pain occurs in the context of both comorbid medical conditions (e.g., cancer, diabetes, obesity) and overlapping comorbid symptoms (e.g., fatigue, sleep deficiency, mood disturbances) that may impact pain and modify effectiveness of interventions. Research in this domain should span the continuum from basic to translational to clinical. Studies of neurobiological and psychosocial mechanisms of pain that strive to isolate pain-specific mechanisms and understand important relationships and connectivity across multiple comorbidities are needed. Efforts to enhance the precision and validity of brain imaging, genetic/genomic and psychosocial methods to distinguish pain from overlapping and confounding factors are especially important. Novel theories and conceptual models that explicitly incorporate putative mediators and moderators of relationships among pain and comorbidities are needed to better understand the human experience of chronic pain. These efforts should be used to inform development and evaluation of more innovative, integrated approaches to clinical assessment and treatment taking into account relevant comorbidities in patients across the life span.

Understand Mechanisms of Childhood Chronic Pain.

Chronic pain often begins in childhood and research has demonstrated that it confers risk for adult chronic pain and psychiatric disorders. In addition, early adversity may alter the central nervous system. Research is needed to understand the developmental mechanisms (e.g., psychological, social, neurobiological) that contribute to chronic pain in children. During sensitive periods in childhood, critical pain memories form and are influenced by social-environmental factors such as parenting behaviors and neurobiological processes. Research is needed to determine the contribution of psychological and social environmental processes in development and maintenance of chronic pain in childhood, characterize the link between early life adversity and subsequent chronic pain, and identify key neurobiological substrates of stress and sex hormones that may contribute to behavioral alterations in pain responses. Availability of psychological and family environment measures, psychophysical pain measures, genetic and immune markers, and brain imaging technologies should accelerate research in this area. In parallel, advances in conceptual models to incorporate developmentally relevant dimensions and to understand basic socio-behavioral mechanisms and processes are needed to explain children’s experience of chronic pain. We need to expand our conceptual understanding of developmentally relevant targets for interventions to reduce or prevent childhood chronic pain. Determining the role of timely intervention in modifying developmental
mechanisms of chronic pain is crucial. Research in this domain will significantly advance understanding of pain mechanisms and is expected to lead to identification of developmentally relevant targets for specific therapies.

**Determine Optimal Safe and Effective Chronic Pain Management.**
Chronic pain management, with or without opioids, requires individualization of treatment. Gaps exist in our knowledge base of the effectiveness of drug and nondrug interventions, in large measure due to the lack of long-term outcomes data of the most commonly employed interventions for chronic pain management. While fully implemented and supported multimodality treatment approaches based on the biopsychosocial model are the long-term goal, a systematic evaluation of the long-term effectiveness of available pharmacologic and non-pharmacologic treatments for chronic pain alone and in combination is needed. The immediate objective is to identify subpopulations of chronic pain patients who benefit from treatments and those that do not. These studies should be extended to define the mechanisms at the preclinical and clinical levels that are responsible for the adverse effects of available treatments (e.g., liability for misuse, addiction and respiratory depression). Studies at the clinical level should include real-world pragmatic trials and randomized controlled trials.

**Determine Optimal Approaches for Use of Self-Management Strategies in Chronic Pain.**
Self-management for pain refers to interventions that can be learned and adopted by an individual or initiated in the context of therapy and subsequently maintained by the individual. Such interventions include physical and mind-body activities (e.g., exercise, yoga, tai chi, meditation, etc.), dietary supplements, over-the-counter medications, behavioral and physical therapies, education about pain, and complementary health approaches. While a number of self-management strategies are promoted, crucial questions remain regarding efficacy and effectiveness, combined use with prescribed treatments, proper dosing, patient adherence, and the identification of biological mechanisms. Research is needed to address these issues and would be facilitated by studies identifying cost-effective and sustainable delivery mechanisms, ways of creating a patient-centric practice culture that values self-management, reduces stigma, and includes self-management in the continuum of care with documentation in the electronic medical record. Self-management is included as a recommendation of many meta-analytic studies, government documents (e.g., National Pain Strategy) and guidelines addressing optimal pain care. Research on this topic would support the shared-decision making process between providers and patients in developing long-term chronic pain management plans.

---

**DISPARITIES**

**Statement of the Problem**
Research over the past several decades has documented major age, sex, gender, racial/ethnic, and socioeconomic group differences in the development and persistence of pain conditions across the life span. For example, women suffer from persistent pain more frequently than men, and there is preclinical evidence that mechanisms which promote persistent pain are molecularly distinct between the sexes.
Moreover, it is increasingly recognized that hormone and neuroendocrine levels, which change across the lifespan and can be dramatically different based on sex, play an important role in mechanisms of transition to persistent pain. The developmental effects of pain and pain treatments may have long term consequences implications for susceptibility for chronic pain throughout the lifespan and need to be explored. Older adults suffer from persistent pain more commonly than all others, yet quality evidence based treatments are lacking. Whereas lower SES has been related to poorer health and poorer pain-related outcomes, the mechanisms driving the SES-pain link are not understood. Moreover, the different components of social economic position factors, both personal resource and environmental, that may be more strongly associated with pain, have yet to be identified. The extent to which SES differences contribute to ethnic group disparities in pain remains poorly understood. Evidence is needed to establish whether and how individual characteristics and patient preferences influence susceptibility to chronic pain, treatment benefits and risks. These mechanisms are still poorly understood and could lead to significant insight into development of personalized medicine for pain.

**Research Priorities**

**Better Define the Epidemiology of Pain in Disparate Populations, Including Children, Women vs. Men, Specific Racial and Ethnic Groups, Older Adults, and Socioeconomically Disadvantaged People.** Research is needed on disparate populations to define the prevalence, incidence, and impact of pain, patterns of treatment, and risk factors that predispose disparate populations to pain. Research is needed to define the epidemiology of single and overlapping pain conditions in disparate populations. These data will help to identify societal consequences of pain in understudied groups, document relative effectiveness of specific treatments, and guide future intervention efforts. New investigations that distinguish between acute and chronic pain should employ standardized questions (e.g., Patient Reported Outcomes Measurement Information System [PROMIS]) to facilitate comparisons across studies, as should longitudinal investigations that document trajectories of specific pain conditions over time. Studies across disparate populations that characterize factors (e.g., clinical, genetic, psychological, metabolic, lifestyle, environmental) that differentially affect risk for pain incidence and/or persistence and investigate interactions between these various factors are particularly encouraged. Studies that document the types of health services received and/or preferred for pain as well as alternative treatments used by these disparate populations are encouraged. Efforts to identify specific mechanisms that underlie the incidence, maintenance, or remission of diverse pain disorders in these populations are needed. Further, analyzing existing data sources (e.g., public and private organizations) that can shed light on the epidemiology and impact of pain in these disparate populations is encouraged.

**Determine Population Group Differences in Outcomes of Pain Treatments.**

Effective pain management requires appropriate assessment and personalized treatment. Furthermore, research is needed to determine whether the safety, efficacy, and comparative effectiveness of existing and emerging pharmacotherapies for acute and chronic pain differ across disparate populations (e.g., races/ethnicities, sex/gender, age/lifespan, socioeconomic status). Research also is needed to determine population group differences in responses to nonpharmacological therapies, with a focus on establishing
their long-term safety and benefits and approaches that can be readily implemented and disseminated widely.

**Investigate Biological, Psychological, Social Mechanisms that Contribute to Population Group Differences in Chronic Pain.**

The burden of chronic pain is unequally distributed across the population, and there is an urgent need to understand the biological and psychosocial factors that drive the disproportionate impact of pain in specific population groups. Research addressing this priority should cover the spectrum of basic, translational, and clinical methodologies and include longitudinal studies that examine changes in mechanisms and their effects over time and across the lifespan. For example, low-income individuals may be at increased risk for pain due to nutritional deficits that occur in early life (in utero and/or childhood), leading to impaired nervous system development, which may interact with psychological factors such as depression to compound the risk for chronic pain. This increased risk may be further compounded or buffered by the quality of social support networks. Research that identifies these fundamental mechanisms will advance our understanding of why differences emerge and/or persist across age, gender, racial/ethnic, and socioeconomic groups, which could inform the development of prevention and intervention strategies that specifically target these underlying factors and reduce pain-related disparities.

**Identify Developmental Periods and Life Stages that Confer Risk for or Protection against Pain Conditions.**

Exposures to negative/positive events in one developmental period can have negative or positive impacts in other life periods. For example, low SES in childhood is strongly associated with decreased psychological and physical functioning and increased mortality in adulthood. Studies are needed to identify specific factors and their mechanisms- that influence the risk of pain occurrence or persistence across the life span, including whether events in one developmental period (e.g., family stress exposure in childhood) predispose to increased (or decreased) risk of pain in another life period. These studies should systematically investigate environmental exposures and risk/protective factors that may differentially influence onset and persistence of pain across life periods, including neonatal, childhood, adolescence, adulthood and late life/end-of-life. In addition, studies are needed that apply biopsychosocial theoretical perspectives to examine how genetic factors, environmental exposures, social resources, SES, and race/ethnicity can lead to cumulative advantages and/or disadvantages over the life course. Studies that examine the independent impact of factors suggested by life course biopsychosocial models as well as their interactions (e.g., gene-environment interactions) across the various periods of the lifespan are needed. Longitudinal studies and innovative design approaches (e.g. cohort/life transition burst designs) are needed to address some of these questions and could offer unique insights into predisposition to pain, help to develop preventive and therapeutic strategies, and inform translation into diverse practice settings.

**Characterize Within-group Variability in the Experience of Pain across Disparate Population Subgroups.**

Considerable research documents between-group differences in the experience of pain across age, gender, racial/ethnic, and socioeconomic categories. There is an urgent need for research that seeks to elucidate this within-group variability in the experience of pain and to elucidate factors (some of which may be group-specific) contributing to this variability, given that there is likely to be more variation – in biological,
psychological, and social factors that are directly relevant to pain – within than between groups. For example, this work may identify protective factors that buffer against the development and persistence of pain among individuals who are members of disparate groups – i.e., groups that are at increased risk for pain. Basic science studies in animal models of pain as well as human studies are needed. Greater understanding of this within-group variability and its potential association to between-group variability in pain will advance efforts to reduce pain-related disparities at the individual- and population group-level.

Evaluate the Impact and Long-Term Consequences of Pharmacological Interventions for Pain Across the Life Span and Specifically on the Developing Nervous Systems of Infants and Children.
A number of studies have targeted acute and chronic pain treatment, and show wide variability in the effectiveness of the approaches for pain relief and improved functioning. Studies typically focus on single treatment approaches (e.g., a specific medication or therapeutic intervention) in a circumscribed population. Thus, little is known about how pain treatments, administered individually or combined, might vary in their efficacy across the lifespan. There also are few data documenting long-term benefits and risks of specific treatments. A striking dearth of studies have documented the efficacy and adverse effects of pharmacological approaches for pain in infants, children, and adolescents, which particularly problematic given the sparse data regarding the impact of pharmacologic pain treatments on the developing nervous system. Therefore, it is critical to conduct high quality studies of individual and multimodal pain treatments with long-term follow-up and include analyses of efficacy and adverse effects in patients across the lifespan.

Determine How the Affective-motivational Components of Pain Contribute to the Overall Pain Experience and Functional Outcomes in Disparate Populations.
Pain is not simply a discriminative sensation generated by nociceptors and activation of pain pathways. Rather, pain is a complex, highly-individual, subjective, perceptual phenomenon with particular emotional qualities that underlie the “unpleasantness” of the experience. The pain experienced by an individual is influenced by motivation, emotions (e.g. empathy and fear), and feelings of relief, past experiences, the social setting and environmental factors. The sensory-discriminative dimensions are associated with processing in the primary and secondary somatosensory cortex. The affective-motivational dimensions of pain reflect the perceived unpleasantness of the painful event and these involve processing in specialized areas of the brain. Pain research has focused on the sensory-discriminative aspects of the response of pain-pathway neurons to the painful event. The relatively few studies that have sought to understand the complex affective-motivational dimensions of pain suggest that these components – including psychological, contextual, anticipatory, and prior experience factors – may powerfully influence the experience and functional outcomes of pain in humans. These factors may be particularly influential in disparate populations such as racial-ethnic minority, socioeconomically disadvantaged, geriatric, pediatric, and gender-specific groups. It is essential to examine how affective-motivational factors uniquely influence pain in each of these disparate groups.

Elucidate Sex-Specific Pain Mechanisms and Determine their Implications for Optimal Treatment of Pain in Females and Males.
Preclinical and clinical evidence reveals sex differences in pain responses. However, sex-specific pain mechanisms that underlie these differences have received relatively little empirical attention. Sex-specific
influences on pain may emerge for multiple reasons. Fundamental biological processes that differ between sexes could play a role. For example, organizational (i.e. developmental) and ongoing effects of sex hormones may generate sex-specific pain mechanisms. In addition, different environmental exposures for females and males could produce sex-specific influences on pain. Female children, adolescents, adults, and seniors remain neglected globally across many cultures through nutritional deprivation, intra-family disparity between male and female genders, and increased work-load among females. In addition to age-dependent hormonal changes, the psychosocial stressors that differ for females versus males may impact pain responses in a sex-specific fashion. There is an urgent need for studies that increase our understanding of sex-specific biological, psychological, and social mechanisms contributing to pain to adequately reduce the increased burden of pain among female. Due to age-dependent hormonal changes, mechanisms are likely to vary at different life stages (e.g. pre- vs. post-puberty, pre- vs. post-menopausal).

Therefore, it is crucial to study sex-specific pain mechanisms across the lifespan. Likewise, sex differences in environmental exposures can vary across ethnic, age, and SES groups. Therefore, sex-specific mechanisms need to be studied across these disparate groups.

**Advance Knowledge of the Relationship between Socioeconomic Status and Pain.**

It is important to determine the extent to which SES drives ethnic group differences in pain, and elucidate the biopsychosocial mechanisms whereby SES influences the development and progression of pain and responses to pain treatment. Social determinants play a key role in a wide variety of health statuses. Some argue that lifestyle, environmental and economic factors are more important than biological factors in the etiology of health and disability. Others argue that the patterning of effects over time may implicate social and economic factors, such as lack of income and wealth, occupational risks, and low educational attainment as fundamental causes of poor health. Others suggest that environmental exposures play a direct role in causing unhealthy conditions, which in turn influence health outcomes. The lack of socioeconomic and related resources, especially long term, is clearly related to help-seeking and access to care and may indirectly influence treatments for physical and mental health conditions related to pain. This is especially true for high impact chronic pain. It has been more difficult to explicate whether social and environmental resource factors play a direct role in the experience of pain. Integrative research adopting a biopsychosocial perspective is needed to: (a) elucidate the associations of SES with psychological and physical pain responses, (b) clarify the contribution of SES to ethnic differences in pain, and (c) understand the potential etiologic role that lack of long term access to social and economic resources plays in the psychological and physical experiences of pain. Recent advances in research have provided innovative tools for understanding the biological underpinnings of lower SES. These tools will allow for analyses of gene-by-gene and gene-by-environment interactions as well as epigenetic and transcriptional changes (e.g. the conserved transcriptional response to adversity) that may serve as potential pathways whereby social, economic, and environmental resource factors influence the nature and experiences of pain.